Cyclacel Pharmaceuticals Stock Price on November 23, 2024
| CYCC Stock | USD 0.35 0.01 2.94% |
Below is the normalized historical share price chart for Cyclacel Pharmaceuticals extending back to March 16, 2004. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Cyclacel Pharmaceuticals stands at 0.35, as last reported on the 27th of November, with the highest price reaching 0.37 and the lowest price hitting 0.34 during the day.
If you're considering investing in Cyclacel Stock, it is important to understand the factors that can impact its price. Cyclacel Pharmaceuticals secures Sharpe Ratio (or Efficiency) of -0.18, which signifies that the company had a -0.18% return per unit of standard deviation over the last 3 months. Cyclacel Pharmaceuticals exposes twenty-one different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Cyclacel Pharmaceuticals' risk adjusted performance of (0.16), and Mean Deviation of 5.07 to double-check the risk estimate we provide.
At present, Cyclacel Pharmaceuticals' Sale Purchase Of Stock is projected to increase significantly based on the last few years of reporting. The current year's Stock Based Compensation To Revenue is expected to grow to 4.94, whereas Total Stockholder Equity is forecasted to decline to about 576.6 K. . At present, Cyclacel Pharmaceuticals' Price To Book Ratio is projected to increase significantly based on the last few years of reporting. The current year's Price Fair Value is expected to grow to 3.93, whereas Price To Sales Ratio is forecasted to decline to 5.91. Cyclacel Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 5th of May 2004 | 200 Day MA 1.6236 | 50 Day MA 0.7768 | Beta 0.557 |
Cyclacel |
Sharpe Ratio = -0.1829
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CYCC |
Estimated Market Risk
| 7.71 actual daily | 68 68% of assets are less volatile |
Expected Return
| -1.41 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.18 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Cyclacel Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cyclacel Pharmaceuticals by adding Cyclacel Pharmaceuticals to a well-diversified portfolio.
Price Book 2.0157 | Enterprise Value Ebitda 0.0179 | Price Sales 27.9781 | Shares Float 1.8 M | Wall Street Target Price 1 |
Related Headline
Ikena Oncology Headline on 22nd of November 2024
Acquisition by Dukes Iain D. of 23419 shares of Ikena Oncolo... by MacroaxisInsider
Filed transaction by Ikena Oncology Director. Grant, award or other acquisition pursuant to Rule 16b-3
Cyclacel Pharmaceuticals Valuation on November 23, 2024
It is possible to determine the worth of Cyclacel Pharmaceuticals on a given historical date. On November 23, 2024 Cyclacel was worth 0.35 at the beginning of the trading date compared to the closed value of 0.36. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Cyclacel Pharmaceuticals stock. Still, in general, we apply an absolute valuation method to find Cyclacel Pharmaceuticals' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cyclacel Pharmaceuticals where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Cyclacel Pharmaceuticals' related companies.
| Open | High | Low | Close | Volume | |
| 0.36 | 0.38 | 0.32 | 0.35 | 364,995 | |
11/22/2024 | 0.35 | 0.38 | 0.35 | 0.36 | 260,562 |
| 0.37 | 0.37 | 0.34 | 0.34 | 179,032 |
| Backtest Cyclacel Pharmaceuticals | | | Cyclacel Pharmaceuticals History | | | Cyclacel Pharmaceuticals Valuation | Previous | Next |
Cyclacel Pharmaceuticals Trading Date Momentum on November 23, 2024
| On November 25 2024 Cyclacel Pharmaceuticals was traded for 0.34 at the closing time. The top price for the day was 0.37 and the lowest listed price was 0.34 . The trading volume for the day was 179 K. The trading history from November 25, 2024 was a factor to the next trading day price decrease. The overall trading delta against the next closing price was 5.56% . The overall trading delta against the current closing price is 5.56% . |
Cyclacel Pharmaceuticals Fundamentals Correlations and Trends
By evaluating Cyclacel Pharmaceuticals' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Cyclacel Pharmaceuticals' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Cyclacel financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Cyclacel Pharmaceuticals Stock history
Cyclacel Pharmaceuticals investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Cyclacel is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Cyclacel Pharmaceuticals will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Cyclacel Pharmaceuticals stock prices may prove useful in developing a viable investing in Cyclacel Pharmaceuticals
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 850.8 K | 893.4 K | |
| Net Loss | -24.6 M | -25.8 M |
Cyclacel Pharmaceuticals Stock Technical Analysis
Cyclacel Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Cyclacel Pharmaceuticals Period Price Range
Low | November 27, 2024
| High |
0.00 | 0.00 |
Cyclacel Pharmaceuticals cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Cyclacel Pharmaceuticals November 27, 2024 Market Strength
Market strength indicators help investors to evaluate how Cyclacel Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Cyclacel Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Cyclacel Pharmaceuticals stock market strength indicators, traders can identify Cyclacel Pharmaceuticals entry and exit signals to maximize returns
Cyclacel Pharmaceuticals Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Cyclacel Pharmaceuticals' price direction in advance. Along with the technical and fundamental analysis of Cyclacel Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Cyclacel to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.16) | |||
| Jensen Alpha | (1.69) | |||
| Total Risk Alpha | (2.81) | |||
| Treynor Ratio | (3.33) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for Cyclacel Stock analysis
When running Cyclacel Pharmaceuticals' price analysis, check to measure Cyclacel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuticals is operating at the current time. Most of Cyclacel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclacel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |